Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
4(57%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
3
43%
Ph phase_4
3
43%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Active, not recruiting2
Terminated1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 33 (42.9%)
Phase 43 (42.9%)

Trials by Status

recruiting229%
active_not_recruiting229%
terminated114%
unknown114%
completed114%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_3

Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis

NCT05252754
active_not_recruitingphase_4

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

NCT04720326
recruitingphase_4

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

NCT06268769
active_not_recruitingphase_4

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

NCT04207177
unknownphase_1

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

NCT04633733
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05252754Phase 3

Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis

Recruiting
NCT04720326Phase 4

Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Active Not Recruiting
NCT06268769Phase 4

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

Recruiting
NCT04207177Phase 4

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Active Not Recruiting
NCT04633733Phase 1

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

Unknown
NCT01325571Phase 3

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Completed
NCT01342016Phase 3

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7